Wolverine Trading LLC Acquires New Shares in Standard BioTools Inc. (NASDAQ:LAB)

Wolverine Trading LLC acquired a new stake in Standard BioTools Inc. (NASDAQ:LAB) in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund acquired 13,808 shares of the company’s stock, valued at approximately $27,000.

Several other institutional investors and hedge funds have also modified their holdings of LAB. Hollow Brook Wealth Management LLC acquired a new stake in shares of Standard BioTools in the 3rd quarter valued at $10,679,000. Sumitomo Mitsui Trust Holdings Inc. lifted its position in Standard BioTools by 20.2% during the 2nd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 10,642,271 shares of the company’s stock worth $18,837,000 after acquiring an additional 1,788,780 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its position in Standard BioTools by 188.6% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 2,445,083 shares of the company’s stock worth $4,719,000 after acquiring an additional 1,597,728 shares during the last quarter. State Street Corp lifted its position in Standard BioTools by 26.7% during the 3rd quarter. State Street Corp now owns 5,495,136 shares of the company’s stock worth $10,606,000 after acquiring an additional 1,157,984 shares during the last quarter. Finally, Bank of New York Mellon Corp lifted its position in Standard BioTools by 1,019.8% during the 2nd quarter. Bank of New York Mellon Corp now owns 980,983 shares of the company’s stock worth $1,736,000 after acquiring an additional 893,383 shares during the last quarter. Institutional investors and hedge funds own 53.74% of the company’s stock.

Wall Street Analyst Weigh In

Separately, TD Cowen cut their target price on shares of Standard BioTools from $2.75 to $2.50 and set a “buy” rating for the company in a research report on Thursday, October 31st.

Standard BioTools Price Performance

Standard BioTools stock opened at $2.21 on Wednesday. The firm has a market cap of $822.69 million, a price-to-earnings ratio of -3.11 and a beta of 1.61. Standard BioTools Inc. has a fifty-two week low of $1.21 and a fifty-two week high of $3.04. The firm has a fifty day moving average price of $1.85 and a two-hundred day moving average price of $1.95.

About Standard BioTools

Standard BioTools Inc, together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument.